Developing a new adjuvant to enhance vaccine effectiveness against bacterial and fungal infections
Official title: DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Funded at University of Montana · NIH-10935819 · Data updated 2026-11-12
This study is testing a new helper ingredient for vaccines called UM-1098, which aims to boost the immune response against tough infections like tuberculosis and certain bacteria, so that people can have better protection from serious illnesses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2023 |
| Award (this year) | $2,419,904 |
| NIH project number | 75N93023C00047-0-9999-1 |
| Project ID | NIH-10935819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would include individuals at high risk for infections caused by the targeted pathogens, such as those with compromised immune systems or chronic respiratory conditions.
✕Less likely to help
Patients who are not at risk for the targeted infections or those who have already been vaccinated with effective vaccines may not receive benefit from this research.
What this research studies
This research focuses on creating a novel synthetic adjuvant, UM-1098, designed to enhance the immune response against various bacterial and fungal pathogens, including tuberculosis and Pseudomonas aeruginosa. The approach involves using a specific receptor ligand and a nanoparticle delivery system that has shown safety and efficacy in animal models. By advancing this adjuvant towards human clinical trials, the research aims to improve vaccination strategies that have been limited by the lack of effective adjuvants for inducing Th17 immunity. Patients may benefit from more effective vaccines that provide better protection against serious infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly improve protection against serious bacterial and fungal infections.
How similar studies have gone: Previous research has shown success with similar approaches in developing adjuvants that enhance immune responses, indicating a promising potential for this novel adjuvant.
Where this research is happening
-
University of Montana
Missoula, United States Active
Researchers
- Principal investigator: Evans, Jay — University of Montana
- Study coordinator: Evans, Jay
Related research
Other NIH-funded projects on the same topics.
-
Doula support to improve mood and anxiety health for rural mothers
A rural-focused program tests whether birth doulas can boost confidence, support, and maternal health for new mothers with mood and anxiety concerns.
-
Telehealth exercise program to help rural breast cancer survivors fight fatigue
A telehealth exercise program is being tested to reduce cancer-related fatigue in rural breast cancer survivors.
-
Behavioral cough suppression and capsaicin for refractory chronic cough
A multi-site study will test how a behavioral therapy for stopping cough works alone and with capsaicin to help people with stubborn chronic cough.
-
Rocky Mountain translational hub to bring discoveries to patients
A Montana hub will speed up turning university discoveries into real health tools that help people, especially in remote states.
-
RDCD Core: Design, Compliance, and Data Management for Montana translational research
A dedicated core helps Montana researchers plan ethical, well-designed studies using big health data and EHRs to advance clinical and translational science.
-
Community Engagement and Outreach Core for Montana Health Research
A state-wide effort to support clinicians and researchers in partnering with communities to design and share health research that reflects local needs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.